The fruit fly Drosophila melanogaster as a screening model for antiseizure medications
- PMID: 39720593
- PMCID: PMC11666373
- DOI: 10.3389/fphar.2024.1489888
The fruit fly Drosophila melanogaster as a screening model for antiseizure medications
Abstract
Objective: Resistance to antiseizure medications (ASMs) is a major challenge in the treatment of patients with epilepsy. Despite numerous newly marketed ASMs, the proportion of drug-resistant people with epilepsy has not significantly decreased over the years. Therefore, novel and innovative seizure models for preclinical drug screening are highly desirable. Here, we explore the efficacy of a broad spectrum of ASMs in suppressing seizure activity in two established Drosophila melanogaster bang-sensitive mutants. These mutants respond with seizures to mechanical stimulation, providing a promising platform for screening novel ASMs.
Methods: Seven frequently used ASMs (brivaracetam, cenobamate, lacosamide, lamotrigine, levetiracetam, phenytoin, and valproate) were administered to the bang-sensitive mutants easily shocked 2F (eas 2F ) and paralytic bss1 (para bss1 ). After 48 h of treatment, the flies were vortexed to induce mechanical stimulation. The seizure probability (i.e., ratio of seizing and non-seizing flies) as well as the seizure duration were analyzed.
Results: In case of eas 2F mutants, treatment with the sodium channel blockers phenytoin and lamotrigine resulted in a robust reduction of seizure probability, whereas flies treated with lacosamide showed a decrease in seizure duration. Treatment with valproate resulted in both a reduction in seizure probability and in seizure duration. In contrast, levetiracetam, brivaracetam and cenobamate had no effect on the bang-sensitive phenotype of eas 2F flies. In case of para bss1 flies, none of the tested medications significantly reduced seizure activity, supporting its role as a model of intractable epilepsy.
Significance: Our results show that particularly sodium channel blockers as well as valproate are effective in suppressing seizure activity in the bang-sensitive mutant eas 2F . These findings demonstrate the usability of Drosophila for screening drugs with antiseizure properties. Due to fewer ethical concerns, the short life cycle, and low maintenance costs, Drosophila might provide an attractive and innovative high-throughput model for the discovery of novel antiseizure compounds.
Keywords: Drosophila melanogaster; animal model; antiseizure medications; drug screening; epilepsy; seizure model.
Copyright © 2024 Fischer, Karge, Koch, Voigt, Weber and Wolking.
Conflict of interest statement
SW has received travel support and speaker honoraria from Angelini Pharma. YW is member of an advisory board of Angelini Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Beghi E., Giussani G., Nichols E., Abd-Allah F., Abdela J., Abdelalim A., et al. (2019). Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology 18 (4), 357–375. 10.1016/s1474-4422(18)30454-x - DOI - PMC - PubMed
-
- Broicher T., Seidenbecher T., Meuth P., Munsch T., Meuth S. G., Kanyshkova T., et al. (2007). T-current related effects of antiepileptic drugs and a Ca2+ channel antagonist on thalamic relay and local circuit interneurons in a rat model of absence epilepsy. Neuropharmacology 53 (3), 431–446. 10.1016/j.neuropharm.2007.05.030 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
